Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β pathway therapies for inflammatory diseases, will be added to the Russell 2000 and Russell 3000 indexes after U.S. markets close on June 26, 2026. Inclusion in these indexes increases Avalo's visibility among investors and may attract more institutional interest. The company is advancing its lead drug abdakibart, which recently showed positive Phase 2 results for hidradenitis suppurativa, and is developing a next-generation antibody, AVTX-010, with plans for IND submission in early 2027. This index addition marks a significant milestone as Avalo continues to develop treatments addressing unmet medical needs.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
